Neglected disease research and development: a pivotal moment for global health
The ninth G-FINDER survey reports on 2015 global investment into research and development (R&D) of new products for neglected diseases, and identifies trends and patterns across the nine years of global G-FINDER data. In all, 185 organisations completed the survey for FY2015, which covered: 39 neglected diseases; 160 product areas for these diseases, including drugs, vaccines, diagnostics, microbicides and vector control products; Platform technologies (adjuvants, delivery technologies, diagnostic platforms) ; All types of product-related R&D, including basic research, discovery and preclinical, clinical development, Phase IV and pharmacovigilance studies, and baseline epidemiological studies.